JP2001158734A - Composition for ophthalmology and method for inhibiting adsorption to soft contact lens - Google Patents
Composition for ophthalmology and method for inhibiting adsorption to soft contact lensInfo
- Publication number
- JP2001158734A JP2001158734A JP34316699A JP34316699A JP2001158734A JP 2001158734 A JP2001158734 A JP 2001158734A JP 34316699 A JP34316699 A JP 34316699A JP 34316699 A JP34316699 A JP 34316699A JP 2001158734 A JP2001158734 A JP 2001158734A
- Authority
- JP
- Japan
- Prior art keywords
- soft contact
- fat
- ophthalmic composition
- soluble vitamins
- contact lens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、ソフトコンタクト
レンズ用の眼科用組成物に関し、更に詳しくは、脂溶性
ビタミン類を含有し、ソフトコンタクトレンズ装用によ
って生じる眼の乾燥感を改善し得るソフトコンタクトレ
ンズ用の眼科用組成物に関する。更に、本発明は、上記
脂溶性ビタミン類のソフトコンタクトレンズに対する吸
着抑制方法に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an ophthalmic composition for a soft contact lens, and more particularly, to a soft contact which contains fat-soluble vitamins and can improve the dry feeling of eyes caused by wearing a soft contact lens. It relates to an ophthalmic composition for a lens. Furthermore, the present invention relates to a method for suppressing the adsorption of the fat-soluble vitamins to a soft contact lens.
【０００２】[0002]
【従来の技術及び発明が解決しようとする課題】コンタ
クトレンズは一般にハードコンタクトレンズとソフトコ
ンタクトレンズに大別することができる。これらコンタ
クトレンズの装用によって、乾き目、疲れ目、かゆみ、
充血などの様々なトラブルが眼に生ずる。特にソフトコ
ンタクトレンズの場合は、装用性が良好であるために、
長時間の装用が可能であり、眼の乾燥感（ドライアイ）
を訴えることが多い。2. Description of the Related Art Contact lenses can be generally classified into hard contact lenses and soft contact lenses. By wearing these contact lenses, dry eyes, tired eyes, itching,
Various troubles such as hyperemia occur in the eyes. Especially in the case of soft contact lenses, the wearability is good,
It can be worn for a long time, and makes the eyes dry (dry eyes)
Often complain.
【０００３】しかしながら、ソフトコンタクトレンズ装
用者のドライアイを改善する組成物はこれまでにはな
く、このドライアイを改善する眼科用組成物の出現が望
まれていた。[0003] However, there has never been a composition for improving the dry eye of a soft contact lens wearer, and an ophthalmic composition for improving the dry eye has been desired.
【０００４】更に、ソフトコンタクトレンズ装着時に
は、眼科用組成物中の成分がレンズに吸着しないことが
望ましい。Furthermore, it is desirable that the components in the ophthalmic composition do not adsorb to the lens when the soft contact lens is worn.
【０００５】本発明は、上記事情に鑑みなされたもの
で、ソフトコンタクトレンズ装用によって生じる眼の乾
燥感を改善するソフトコンタクトレンズ用の眼科用組成
物及びソフトコンタクトレンズに対する吸着抑制方法を
提供することを目的とする。The present invention has been made in view of the above circumstances, and provides an ophthalmic composition for a soft contact lens and a method for suppressing adsorption to the soft contact lens, which improve the dry feeling of the eye caused by wearing the soft contact lens. With the goal.
【０００６】[0006]
【課題を解決するための手段及び発明の実施の形態】本
発明者らは、上記課題を解決するために鋭意検討を行っ
た結果、脂溶性ビタミン類を配合することにより眼の乾
燥感を改善することができることを見い出し、本発明を
なすに至った。更に、本発明者らは、脂溶性ビタミン類
を含有してなるソフトコンタクトレンズ用の眼科用組成
物に高分子化合物及び／又は非イオン性界面活性剤を配
合することによって、脂溶性ビタミン類のソフトコンタ
クトレンズに対する吸着が抑制されることを見い出し、
本発明をなすに至った。Means for Solving the Problems and Embodiments of the Invention The present inventors have conducted intensive studies in order to solve the above-mentioned problems, and as a result, improved the dry feeling of eyes by adding fat-soluble vitamins. The inventors have found that the present invention can be performed, and have accomplished the present invention. Furthermore, the present inventors blended a high molecular compound and / or a nonionic surfactant into an ophthalmic composition for soft contact lenses containing fat-soluble vitamins, thereby producing fat-soluble vitamins. We found that adsorption to soft contact lenses was suppressed,
The present invention has been made.
【０００７】即ち、本発明は、（１）脂溶性ビタミン類
を含有してなるソフトコンタクトレンズ用の眼科用組成
物、より好ましくは、更に、高分子化合物及び／又は非
イオン性界面活性剤を配合してなる眼科用組成物、
（２）脂溶性ビタミン類を含有してなる眼科用組成物
に、高分子化合物及び／又は非イオン性界面活性剤を配
合することを特徴とする脂溶性ビタミン類のソフトコン
タクトレンズに対する吸着抑制方法を提供する。That is, the present invention relates to (1) an ophthalmic composition for a soft contact lens containing a fat-soluble vitamin, more preferably a polymer compound and / or a nonionic surfactant. Ophthalmic composition,
(2) A method for suppressing adsorption of fat-soluble vitamins to soft contact lenses, which comprises blending a polymer compound and / or a nonionic surfactant with an ophthalmic composition containing fat-soluble vitamins. I will provide a.
【０００８】以下、本発明につき、更に記述すると、本
発明の眼科用組成物は、脂溶性ビタミン類を必須成分と
して含有するものである。Hereinafter, the present invention will be further described. The ophthalmic composition of the present invention contains a fat-soluble vitamin as an essential component.
【０００９】ここで、本発明において、脂溶性ビタミン
類としては、例えばビタミンＡ、パルミチン酸レチノー
ル、酢酸レチノール、ビタミンＡ油などのビタミンＡ
類、トコフェロール、酢酸トコフェロール、コハク酸ト
コフェロールなどのビタミンＥ類等が挙げられ、これら
は１種単独で又は２種以上を適宜組み合わせて使用する
ことができる。本発明の場合、これらの中でもパルミチ
ン酸レチノールが特に好適である。パルミチン酸レチノ
ールは、通常１ｇ中に１００万〜１８０万国際単位（以
下Ｉ．Ｕ．と略記）を含むものが市販されており、具体
的には、ロシュ・ビタミン・ジャパン株式会社製パルミ
チン酸レチノール１７０万Ｉ．Ｕ．等がある。In the present invention, the fat-soluble vitamins include, for example, vitamin A, such as vitamin A, retinol palmitate, retinol acetate, and vitamin A oil.
And vitamin Es such as tocopherol, tocopherol acetate, and tocopherol succinate. These can be used alone or in an appropriate combination of two or more. In the case of the present invention, among these, retinol palmitate is particularly preferred. As for retinol palmitate, one containing 1 million to 1.8 million international units (hereinafter abbreviated as IU) in 1 g is commercially available. Specifically, retinol palmitate manufactured by Roche Vitamin Japan Co., Ltd. 1.7 million I. U. Etc.
【００１０】本発明の眼科用組成物における上記脂溶性
ビタミン類の配合量は、その種類などによって適宜選定
することができ、例えばビタミンＡ類であれば、通常、
組成物中に０．００１〜０．２ｗ／ｖ％（質量／容量
％、以下同様）、即ち、１０００〜３６００００Ｉ．
Ｕ．／１００ｍｌ配合することができ、好ましくは０．
０１〜０．１ｗ／ｖ％、即ち、１００００〜１８０００
０Ｉ．Ｕ．／１００ｍｌの範囲である。ビタミンＥ類
は、通常、０．００５〜０．２ｗ／ｖ％配合することが
でき、好ましくは０．０１〜０．１ｗ／ｖ％の範囲であ
る。[0010] The amount of the fat-soluble vitamins in the ophthalmic composition of the present invention can be appropriately selected depending on the type and the like.
0.001 to 0.2 w / v% (mass / volume%, hereinafter the same) in the composition, that is, 1000 to 360,000 I.V.
U. / 100 ml, preferably 0.1 ml.
01 to 0.1 w / v%, that is, 10,000 to 18000
0I. U. / 100 ml. Vitamin E can be generally added in an amount of 0.005 to 0.2 w / v%, preferably in the range of 0.01 to 0.1 w / v%.
【００１１】このように脂溶性ビタミン類を配合した本
発明のソフトコンタクトレンズ用の眼科用組成物は、ソ
フトコンタクトレンズ用のあらゆる眼科用途の組成物に
使用することができる。具体的には、ソフトコンタクト
レンズ用の乾き目改善点眼剤等として使用される。The ophthalmic composition for a soft contact lens of the present invention containing the fat-soluble vitamins as described above can be used for any ophthalmic composition for a soft contact lens. Specifically, it is used as an ophthalmic solution for improving dry eyes for soft contact lenses.
【００１２】ここで、本発明の眼科用組成物は、更に、
高分子化合物及び／又は非イオン性界面活性剤を配合す
ると、より好適であり、本発明のソフトコンタクトレン
ズに対する吸着抑制方法は、このように上記脂溶性ビタ
ミン類を含有してなる眼科用組成物に、上記高分子化合
物及び／又は非イオン性界面活性剤を配合することによ
って、ソフトコンタクトレンズを装用した使用者に適用
しても、脂溶性ビタミン類がソフトコンタクトレンズに
吸着することを抑制できるものである。Here, the ophthalmic composition of the present invention further comprises:
It is more preferable to mix a polymer compound and / or a nonionic surfactant, and the method for suppressing adsorption to a soft contact lens according to the present invention is described in the above. In addition, by blending the polymer compound and / or the nonionic surfactant, even when applied to a user wearing a soft contact lens, fat-soluble vitamins can be suppressed from adsorbing to the soft contact lens. Things.
【００１３】本発明における高分子化合物としては、ポ
リビニルアルコール、ポリビニルピロリドン、ヒドロキ
シエチルセルロース、ヒドロキシプロピルメチルセルロ
ース、メチルセルロース、シクロデキストリン等が挙げ
られ、これらは１種単独で又は２種以上を適宜組み合わ
せて使用することができる。本発明の場合、これらの中
でも特にメチルセルロース、シクロデキストリン等がよ
り好適である。Examples of the polymer compound in the present invention include polyvinyl alcohol, polyvinylpyrrolidone, hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose, cyclodextrin and the like. These may be used alone or in combination of two or more. be able to. In the case of the present invention, among these, methyl cellulose, cyclodextrin and the like are particularly preferable.
【００１４】本発明の眼科用組成物におけるこれらの高
分子化合物の配合量は、その種類などにより適宜選定す
ることができ、例えばメチルセルロース、ヒドロキシエ
チルセルロース、ヒドロキシプロピルメチルセルロース
であれば、通常、組成物中に好ましくは０．０１〜５ｗ
／ｖ％、より好ましくは０．０５〜１ｗ／ｖ％、シクロ
デキストリンであれば、好ましくは０．００１〜５ｗ／
ｖ％、より好ましくは０．００５〜２ｗ／ｖ％、ポリビ
ニルアルコール、ポリビニルピロリドンであれば、好ま
しくは０．０１〜１０ｗ／ｖ％、より好ましくは０．１
〜５ｗ／ｖ％の範囲で配合することができる。The amount of these polymer compounds in the ophthalmic composition of the present invention can be appropriately selected depending on the kind and the like. For example, methyl cellulose, hydroxyethyl cellulose and hydroxypropyl methyl cellulose are usually used in the composition. Preferably 0.01 to 5 w
/ V%, more preferably 0.05 to 1 w / v%, if it is cyclodextrin, preferably 0.001 to 5 w / v%.
v%, more preferably 0.005 to 2 w / v%, for polyvinyl alcohol or polyvinylpyrrolidone, preferably 0.01 to 10 w / v%, more preferably 0.1
It can be blended in the range of ５5 w / v%.
【００１５】また、上記脂溶性ビタミン類に対して１０
〜５０００質量％配合することが望ましい。上記高分子
化合物が脂溶性ビタミン類に対して１０質量％未満であ
ると脂溶性ビタミン類の吸着を抑制することが困難な場
合があり、また、組成物中の配合量が多すぎると眼への
刺激性が強くなる等の問題を生じる。In addition, 10 to the above fat-soluble vitamins
It is desirable to mix 5000 mass%. When the amount of the polymer compound is less than 10% by mass with respect to the fat-soluble vitamins, it may be difficult to suppress the adsorption of the fat-soluble vitamins. This causes problems such as increased irritation.
【００１６】本発明における非イオン性界面活性剤とし
ては、水溶性のポリオキシエチレン硬化ヒマシ油等のポ
リオキシエチレン高級脂肪酸エステル、ポリオキシエチ
レンソルビタン高級脂肪酸エステル等が挙げられ、より
具体的には、例えばポリオキシエチレン（ｐ＝６０）硬
化ヒマシ油、ポリオキシエチレン（ｐ＝２０）ソルビタ
ンモノオレエート等が挙げられる。ここで、ｐはエチレ
ンオキシドの平均付加モル数を示す。Examples of the nonionic surfactant in the present invention include polyoxyethylene higher fatty acid esters such as water-soluble polyoxyethylene hydrogenated castor oil, and polyoxyethylene sorbitan higher fatty acid esters. For example, polyoxyethylene (p = 60) hydrogenated castor oil, polyoxyethylene (p = 20) sorbitan monooleate and the like can be mentioned. Here, p indicates the average number of moles of ethylene oxide added.
【００１７】本発明の眼科用組成物における非イオン性
界面活性剤の配合量は、特に制限されるものではなく、
通常、組成物中に好ましくは０．０１〜１ｗ／ｖ％、よ
り好ましくは０．０５〜０．５ｗ／ｖ％の範囲で配合す
ると好適である。また、上記脂溶性ビタミン類に対して
１００〜１０００質量％配合すると好適である。非イオ
ン性界面活性剤が脂溶性ビタミン類に対して１００質量
％未満であると脂溶性ビタミン類の吸着を抑制すること
が困難な場合があり、また、組成物中の配合量が１ｗ／
ｖ％を超えると眼への刺激性が強くなる等の問題を生じ
る場合がある。The amount of the nonionic surfactant in the ophthalmic composition of the present invention is not particularly limited.
Usually, it is suitable to mix in the composition preferably in the range of 0.01 to 1 w / v%, more preferably 0.05 to 0.5 w / v%. Further, it is preferable to mix 100 to 1000% by mass with respect to the fat-soluble vitamins. If the amount of the nonionic surfactant is less than 100% by mass relative to the fat-soluble vitamins, it may be difficult to suppress the adsorption of the fat-soluble vitamins, and the compounding amount in the composition may be 1 w /
If it exceeds v%, problems such as increased irritation to the eyes may occur.
【００１８】本発明のソフトコンタクトレンズ用の眼科
用組成物の形状としては、例えば点眼剤、眼軟膏剤、ゲ
ル剤、用時溶解により液状となる固形製剤等が挙げられ
るが、好ましくは点眼剤の形態である。Examples of the shape of the ophthalmic composition for the soft contact lens of the present invention include eye drops, eye ointments, gels, and solid preparations which become liquid upon dissolution, and are preferably eye drops. It is a form of.
【００１９】本発明においては、前記した必須成分の他
に前記した点眼剤、眼軟膏剤、ゲル剤等の製剤の調製に
通常使用する全ての緩衝剤、溶解補助剤、等張化剤、安
定化剤、粘稠剤、キレート剤、ｐＨ調整剤、清涼化剤等
の各種の添加剤、およびその他の薬学的有効成分などを
通常使用量において配合することができる。In the present invention, in addition to the above-mentioned essential components, all buffers, dissolution aids, isotonic agents, and stabilizing agents usually used in the preparation of eye drops, eye ointments, gels, etc. Various additives such as an agent, a thickening agent, a chelating agent, a pH adjuster, a cooling agent, and other pharmaceutically active ingredients can be blended in a usual amount.
【００２０】より具体的には、緩衝剤としては、例えば
ホウ酸又はその塩（ホウ砂等）、クエン酸又はその塩
（クエン酸ナトリウム等）、リン酸又はその塩（リン酸
一水素ナトリウム等）、酒石酸又はその塩（酒石酸ナト
リウム等）、グルコン酸又はその塩（グルコン酸ナトリ
ウム等）、酢酸又はその塩（酢酸ナトリウム等）、各種
アミノ酸等又はそれらの組み合わせなどが挙げられる。More specifically, examples of the buffer include boric acid or a salt thereof (borax or the like), citric acid or a salt thereof (sodium citrate or the like), phosphoric acid or a salt thereof (sodium monohydrogen phosphate or the like) ), Tartaric acid or a salt thereof (such as sodium tartrate), gluconic acid or a salt thereof (such as sodium gluconate), acetic acid or a salt thereof (such as sodium acetate), various amino acids, or a combination thereof.
【００２１】溶解補助剤としては、例えばポリエチレン
グリコール、プロピレングリコール等が挙げられる。等
張化剤としては、例えば、塩化ナトリウム、塩化カリウ
ム、マンニトール、プロピレングリコール等が挙げられ
る。安定化剤としては、例えばエデト酸ナトリウム、シ
クロデキストリン、亜硫酸塩、クエン酸又はその塩等が
挙げられる。Examples of the solubilizer include polyethylene glycol and propylene glycol. Examples of the tonicity agent include sodium chloride, potassium chloride, mannitol, propylene glycol and the like. Examples of the stabilizer include sodium edetate, cyclodextrin, sulfite, citric acid, and salts thereof.
【００２２】粘稠剤としては、例えばポリエチレングリ
コール、ポリビニルアルコール、ポリビニルピロリド
ン、ヒドロキシエチルセルロース、ヒドロキシプロピル
メチルセルロース、メチルセルロース、コンドロイチン
硫酸ナトリウム等が挙げられる。キレート剤としては、
例えばエデト酸ナトリウム、クエン酸ナトリウム等が挙
げられる。Examples of the thickener include polyethylene glycol, polyvinyl alcohol, polyvinyl pyrrolidone, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, methyl cellulose, sodium chondroitin sulfate and the like. As chelating agents,
For example, sodium edetate, sodium citrate and the like can be mentioned.
【００２３】ｐＨ調整剤としては、例えば塩酸、クエン
酸又はその塩、ホウ酸又その塩、リン酸又はその塩、酢
酸又はその塩、酒石酸又はその塩、水酸化ナトリウム、
水酸化カリウム、炭酸ナトリウム、炭酸水素ナトリウム
等が挙げられる。清涼化剤としては、例えばメントー
ル、ボルネオール、カンフル、ゲラニオール、リモネ
ン、オイゲノール、ハッカ油、ユーカリ油等が挙げられ
る。Examples of the pH adjuster include hydrochloric acid, citric acid or a salt thereof, boric acid or a salt thereof, phosphoric acid or a salt thereof, acetic acid or a salt thereof, tartaric acid or a salt thereof, sodium hydroxide,
Potassium hydroxide, sodium carbonate, sodium hydrogen carbonate and the like can be mentioned. Examples of the cooling agent include menthol, borneol, camphor, geraniol, limonene, eugenol, peppermint oil, eucalyptus oil and the like.
【００２４】薬学的有効成分としては、例えば充血除去
剤（塩酸ナファゾリン、塩酸テトラヒドロゾリン、塩酸
フェニレフリン等）、消炎・収斂剤（メチル硫酸ネオス
チグミン、イプシロン−アミノカプロン酸、アラントイ
ン、塩化ベルベリン、硫酸亜鉛、塩化リゾチーム等）、
抗ヒスタミン剤（塩酸ジフェンヒドラミン、塩酸イソチ
ペンジル、マレイン酸クロルフェニラミン等）、水溶性
ビタミン類［活性型ビタミンＢ2、ビタミンＢ6、ビタミ
ンＢ12］、アミノ酸類（Ｌ−アスパラギン酸カリウム、
Ｌ−アスパラギン酸マグネシウム、アミノエチルスルホ
ン酸、コンドロイチン硫酸ナトリウム等）、サルファ
剤、殺菌剤（イオウ、イソプロピルメチルフェノール、
ヒノキチオール等）、局所麻酔剤（リドカイン、塩酸リ
ドカイン、塩酸プロカイン、塩酸ジブカイン等）などを
適宜配合することができる。Examples of the pharmaceutically active ingredient include decongestants (naphazoline hydrochloride, tetrahydrozoline hydrochloride, phenylephrine hydrochloride, etc.), anti-inflammatory and astringents (neostigmine methyl sulfate, epsilon-aminocaproic acid, allantoin, berberine chloride, zinc sulfate, lysozyme chloride) etc),
Antihistamines (diphenhydramine hydrochloride, isotipendyl hydrochloride, chlorpheniramine maleate, etc.), water-soluble vitamins [active vitamin B 2 , vitamin B 6 , vitamin B 12 ], amino acids (potassium L-aspartate,
Magnesium L-aspartate, aminoethylsulfonic acid, chondroitin sulfate, etc.), sulfa drugs, fungicides (sulfur, isopropylmethylphenol,
Hinokitiol, etc.) and local anesthetics (lidocaine, lidocaine hydrochloride, procaine hydrochloride, dibucaine hydrochloride, etc.) and the like can be appropriately compounded.
【００２５】本発明の眼科用組成物のｐＨは、眼科的に
許容される範囲であれば特に制限はなく、通常ｐＨ４〜
９の範囲であり、好ましくは５〜８．５である。The pH of the ophthalmic composition of the present invention is not particularly limited as long as it is within an ophthalmologically acceptable range.
9 and preferably 5 to 8.5.
【００２６】本発明の眼科用組成物の調製方法は特に問
わないが、例えば、点眼剤の場合は、脂溶性ビタミン類
を、まず、非イオン性界面活性剤により滅菌精製水に可
溶化し、ついで高分子化合物等の各配合成分を加えてｐ
Ｈを調整することにより得られる。The method for preparing the ophthalmic composition of the present invention is not particularly limited. For example, in the case of eye drops, fat-soluble vitamins are first solubilized in sterile purified water with a nonionic surfactant, Then, each compounding component such as a polymer compound is added and p
It is obtained by adjusting H.
【００２７】本発明のソフトコンタクトレンズ用眼科用
組成物の投与量は、眼科的に許容される範囲であれば特
に制限はないが、例えば点眼剤として用いる場合、１回
量１〜３滴を１日４〜６回投与することが好ましい。The dosage of the ophthalmic composition for a soft contact lens of the present invention is not particularly limited as long as it is ophthalmically acceptable. For example, when used as eye drops, one to three drops may be used. It is preferable to administer 4 to 6 times a day.
【００２８】[0028]
【実施例】以下に、実施例及び比較例を挙げて本発明を
更に詳細に説明するが、本発明は、下記実施例によって
なんら限定されるものではない。The present invention will be described in more detail with reference to the following Examples and Comparative Examples, but the present invention is not limited to the following Examples.
【００２９】［実施例１及び比較例１］表１に示す組成
に従って常法により点眼剤を調製した。ソフトコンタク
トレンズを装着している被験者６名について、片眼に実
施例１の処方の点眼剤を、反対の眼に比較例１の処方の
点眼剤をそれぞれ２〜３滴点眼し、それぞれの眼につい
てソフトコンタクトレンズ装着による眼の乾燥感の改善
度合いを調べた。得られた結果を以下の評価基準に従っ
て評価した。結果を表２に示す。Example 1 and Comparative Example 1 Eye drops were prepared according to the composition shown in Table 1 by a conventional method. For 6 subjects wearing soft contact lenses, the eye drops of the prescription of Example 1 were applied to one eye, and the eye drops of the prescription of Comparative Example 1 were applied to the opposite eye in 2-3 drops. The degree of improvement in the dryness of the eyes by wearing a soft contact lens was examined. The obtained results were evaluated according to the following evaluation criteria. Table 2 shows the results.
【００３０】評価基準 ５点：乾燥感が改善した ４点：乾燥感がやや改善した ３点：乾燥感が変わらない ２点：乾燥感がややひどくなった １点：乾燥感がひどくなった Evaluation criteria 5 points: Dry feeling improved 4 points: Dry feeling slightly improved 3 points: Dry feeling did not change 2 points: Dry feeling became slightly worse 1 point: Dry feeling became severe
【００３１】[0031]
【表１】 [Table 1]
【００３２】[0032]
【表２】 [Table 2]
【００３３】表２の結果から明らかなように、脂溶性ビ
タミン類を含有した実施例１を点眼した眼は乾燥感が改
善されたが、脂溶性ビタミン類を含まない比較例１を点
眼した眼ではほとんど変化がなかった。このことより、
脂溶性ビタミン類を含有する眼科用組成物の点眼によ
り、ソフトコンタクトレンズ装着による眼の乾燥感を改
善することが確認された。As is evident from the results in Table 2, the eyes treated with Example 1 containing fat-soluble vitamins had an improved dry feeling, but the eyes treated with Comparative Example 1 containing no fat-soluble vitamins. Then there was little change. From this,
Instillation of the ophthalmic composition containing fat-soluble vitamins was confirmed to improve the dryness of the eyes due to wearing of a soft contact lens.
【００３４】［実施例２、３及び参考例１］表３に示す
組成に従って常法により点眼剤を調製した。以下に示す
ように、これを試験液として、パルミチン酸レチノール
のソフトコンタクトレンズに対する吸着試験を行った。Examples 2, 3 and Reference Example 1 Eye drops were prepared according to the composition shown in Table 3 by a conventional method. As shown below, using this as a test solution, an adsorption test of retinol palmitate to a soft contact lens was performed.
【００３５】＜吸着試験＞試験液をそれぞれバイアル瓶
に正確に５ｍｌ量り取り、ソフトコンタクトレンズ１枚
を浸漬した。この時、ソフトコンタクトレンズを浸漬し
ない液を対照とした。バイアル瓶を３７℃で７日間振と
うした後に、試験液中のパルミチン酸レチノール含量を
測定し、対照液との差をソフトコンタクトレンズへの吸
着量とした。パルミチン酸レチノールは、高速液体クロ
マトグラフ法により定量した。得られた結果を表３に併
記する。<Adsorption Test> Each test solution was accurately weighed in a vial bottle in an amount of 5 ml, and one soft contact lens was immersed. At this time, a liquid in which the soft contact lens was not immersed was used as a control. After shaking the vial at 37 ° C. for 7 days, the content of retinol palmitate in the test solution was measured, and the difference from the control solution was defined as the amount of adsorption to the soft contact lens. Retinol palmitate was quantified by high performance liquid chromatography. Table 3 also shows the obtained results.
【００３６】[0036]
【表３】 [Table 3]
【００３７】表３の結果によれば、高分子化合物及び／
又は非イオン性界面活性剤を配合した点眼剤は、ソフト
コンタクトレンズに対する脂溶性ビタミン類の吸着が抑
制されることが認められる。According to the results shown in Table 3, the polymer compound and / or
Alternatively, it is recognized that eye drops containing a nonionic surfactant suppress the adsorption of fat-soluble vitamins to soft contact lenses.
【００３８】［実施例４〜３１］表４〜７に示す組成に
従って常法により点眼剤を調製し、ソフトコンタクトレ
ンズ装用者１０名に上記実施例１と同様の評価基準で眼
の乾燥感の改善度合いを評価させたところ、乾燥感の改
善度合いは、ビタミンＡ類が特に優れていた。評価結果
については、１０人中最も多かった点数を表中に併記し
た。なお、下記実施例の点眼剤に配合された脂溶性ビタ
ミン類の吸着性を上記吸着試験に準じて確認したとこ
ろ、いずれも脂溶性ビタミン類の吸着が抑制されてい
た。[Examples 4 to 31] Eye drops were prepared by a conventional method according to the compositions shown in Tables 4 to 7, and the dryness of eyes was evaluated by the same evaluation criteria as in Example 1 above for 10 soft contact lens wearers. When the degree of improvement was evaluated, the degree of improvement in the dry feeling was particularly excellent for vitamins A. Regarding the evaluation results, the highest score out of 10 persons is also shown in the table. In addition, when the adsorptivity of fat-soluble vitamins blended in the eye drops of the following examples was confirmed according to the above-mentioned adsorption test, the adsorption of fat-soluble vitamins was suppressed in all cases.
【００３９】[0039]
【表４】 [Table 4]
【００４０】[0040]
【表５】 [Table 5]
【００４１】[0041]
【表６】 [Table 6]
【００４２】[0042]
【表７】 [Table 7]
【００４３】[0043]
【発明の効果】本発明によれば、ソフトコンタクトレン
ズ用の眼科用組成物に脂溶性ビタミン類を配合すること
によって、ソフトコンタクトレンズ装用により生じる眼
の乾燥感を改善し得るソフトコンタクトレンズ用の眼科
用組成物が得られる。更に、本発明によれば、ソフトコ
ンタクトレンズ用の眼科用組成物に配合された脂溶性ビ
タミン類のソフトコンタクトレンズに対する吸着を抑制
することができる。Industrial Applicability According to the present invention, a fat-soluble vitamin is added to an ophthalmic composition for a soft contact lens, whereby the dry feeling of the eye caused by wearing the soft contact lens can be improved. An ophthalmic composition is obtained. Furthermore, according to the present invention, the adsorption of fat-soluble vitamins blended in the ophthalmic composition for soft contact lenses to the soft contact lenses can be suppressed.
Claims (3)
コンタクトレンズ用の眼科用組成物。1. An ophthalmic composition for a soft contact lens, comprising a fat-soluble vitamin.
性界面活性剤を配合してなる請求項１記載の眼科用組成
物。2. The ophthalmic composition according to claim 1, further comprising a polymer compound and / or a nonionic surfactant.
組成物に、高分子化合物及び／又は非イオン性界面活性
剤を配合することを特徴とする脂溶性ビタミン類のソフ
トコンタクトレンズに対する吸着抑制方法。3. Adsorption of fat-soluble vitamins to a soft contact lens, characterized in that a polymer compound and / or a nonionic surfactant is blended with an ophthalmic composition containing fat-soluble vitamins. Suppression method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP34316699A JP2001158734A (en) | 1999-12-02 | 1999-12-02 | Composition for ophthalmology and method for inhibiting adsorption to soft contact lens |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP34316699A JP2001158734A (en) | 1999-12-02 | 1999-12-02 | Composition for ophthalmology and method for inhibiting adsorption to soft contact lens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2001158734A true JP2001158734A (en) | 2001-06-12 |
Family
ID=18359430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP34316699A Pending JP2001158734A (en) | 1999-12-02 | 1999-12-02 | Composition for ophthalmology and method for inhibiting adsorption to soft contact lens |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2001158734A (en) |
Cited By (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002049613A3 (en) * | 2000-12-19 | 2003-01-16 | Bausch & Lomb | Method for enhancing integrity of epithelium using retinoic acid |
| JP2003066383A (en) * | 2001-08-30 | 2003-03-05 | Lion Corp | Contact lens wearing liquid |
| JP2005037928A (en) * | 2003-06-26 | 2005-02-10 | Rohto Pharmaceut Co Ltd | Composition of contact lense |
| WO2007077783A1 (en) | 2005-12-27 | 2007-07-12 | Lion Corporation | Composition for soft contact lens and adsorption suppressing method |
| JP2011006348A (en) * | 2009-06-25 | 2011-01-13 | Lion Corp | Therapeutic agent for dry eye |
| JP2012145967A (en) * | 2012-05-07 | 2012-08-02 | Lion Corp | Contact lens wetting solution |
| JP2012189993A (en) * | 2011-03-10 | 2012-10-04 | Pegavision Corp | Liquid composition for contact lenses |
| JP2015531344A (en) * | 2012-09-12 | 2015-11-02 | ノバリック ゲーエムベーハー | Composition comprising a mixture of semi-fluorinated alkanes |
| US10058615B2 (en) | 2012-09-12 | 2018-08-28 | Novaliq Gmbh | Semifluorinated alkane compositions |
| US10064944B2 (en) | 2010-11-11 | 2018-09-04 | Novaliq Gmbh | Liquid pharmaceutical composition for the treatment of a posterior eye disease |
| US10130707B2 (en) | 2011-05-25 | 2018-11-20 | Novaliq Gmbh | Topical pharmaceutical composition based on semifluorinated alkanes |
| JP2019065008A (en) * | 2017-10-04 | 2019-04-25 | ライオン株式会社 | Ophthalmic composition, method for producing the same, and method for suppressing adsorption |
| US10273298B2 (en) | 2013-07-23 | 2019-04-30 | Novaliq Gmbh | Stabilized antibody compositions |
| WO2019216381A1 (en) * | 2018-05-09 | 2019-11-14 | ロート製薬株式会社 | Ophthalmic composition |
| US10507132B2 (en) | 2016-06-23 | 2019-12-17 | Novaliq Gmbh | Topical administration method |
| US10525159B2 (en) | 2016-05-26 | 2020-01-07 | Ophtecs Corporation | Liquid preparation for contact lenses comprising hydrolyzed hyaluronic acid derivative and cationic bactericide |
| US10555953B2 (en) | 2010-03-17 | 2020-02-11 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
| US10682315B2 (en) | 2015-09-30 | 2020-06-16 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
| US10813976B2 (en) | 2016-09-23 | 2020-10-27 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| US11154513B2 (en) | 2015-09-30 | 2021-10-26 | Novaliq Gmbh | Semifluorinated compounds |
| US11160865B2 (en) | 2010-10-20 | 2021-11-02 | Novaliq Gmbh | Liquid pharmaceutical composition for the delivery of active ingredients |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| US11413323B2 (en) | 2018-10-12 | 2022-08-16 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| US11576893B2 (en) | 2018-03-02 | 2023-02-14 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
| US11684589B2 (en) | 2016-09-22 | 2023-06-27 | Novaliq Gmbh | Pharmaceutical compositions for use in the therapy of blepharitis |
| US11723861B2 (en) | 2017-09-27 | 2023-08-15 | Novaliq Gmbh | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases |
| USRE49758E1 (en) | 2012-01-23 | 2023-12-19 | Novaliq Gmbh | Stabilised protein compositions based on semifluorinated alkanes |
| US11896559B2 (en) | 2017-10-04 | 2024-02-13 | Novaliq Gmbh | Opthalmic compositions comprising F6H8 |
| US12005033B2 (en) | 2012-09-12 | 2024-06-11 | Novaliq Gmbh | Compositions comprising mixtures of semifluorinated alkanes |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63208516A (en) * | 1986-09-04 | 1988-08-30 | ビジヨン フアーマシユーテイカルス、インコーポレーテツド | Ophthalmic medicine containing vitamin a composition and remedy for dry and inflammatory eye |
| JPH04300830A (en) * | 1991-03-28 | 1992-10-23 | Zeria Pharmaceut Co Ltd | Aqueous solution of vitamin es |
| JPH07199131A (en) * | 1993-06-30 | 1995-08-04 | Essilor Internatl (Cie Gen Opt) | Method for avoiding accumulation of protein on surface of synthesized polymers used in contact with biological system |
| JPH08500382A (en) * | 1992-08-25 | 1996-01-16 | シヤーマン，ガイ・ジエイ | Preservative system for ophthalmic solutions and contact lens solutions and method for cleaning, disinfecting and preserving contact lenses |
| JPH0866471A (en) * | 1994-08-22 | 1996-03-12 | Becton Dickinson & Co | Water soluble lubricant for medical device |
| JPH08175985A (en) * | 1994-12-26 | 1996-07-09 | Lion Corp | Ophthalmic solution |
| JPH0977656A (en) * | 1995-09-14 | 1997-03-25 | Toshihiro Handa | Aerosol composition for dropping eye lotion |
| JPH09255530A (en) * | 1996-03-25 | 1997-09-30 | Shiseido Co Ltd | Solubilized cosmetic |
| JPH10505067A (en) * | 1994-08-30 | 1998-05-19 | アラーガン | Compositions and methods for disinfecting contact lenses with terpenes |
| JPH11130667A (en) * | 1997-08-26 | 1999-05-18 | Senju Pharmaceut Co Ltd | Ophthalmic composition for soft contact lens, wetting enhancement of soft contact lens and adsorption suppression of terpenoid |
-
1999
- 1999-12-02 JP JP34316699A patent/JP2001158734A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63208516A (en) * | 1986-09-04 | 1988-08-30 | ビジヨン フアーマシユーテイカルス、インコーポレーテツド | Ophthalmic medicine containing vitamin a composition and remedy for dry and inflammatory eye |
| JPH04300830A (en) * | 1991-03-28 | 1992-10-23 | Zeria Pharmaceut Co Ltd | Aqueous solution of vitamin es |
| JPH08500382A (en) * | 1992-08-25 | 1996-01-16 | シヤーマン，ガイ・ジエイ | Preservative system for ophthalmic solutions and contact lens solutions and method for cleaning, disinfecting and preserving contact lenses |
| JPH07199131A (en) * | 1993-06-30 | 1995-08-04 | Essilor Internatl (Cie Gen Opt) | Method for avoiding accumulation of protein on surface of synthesized polymers used in contact with biological system |
| JPH0866471A (en) * | 1994-08-22 | 1996-03-12 | Becton Dickinson & Co | Water soluble lubricant for medical device |
| JPH10505067A (en) * | 1994-08-30 | 1998-05-19 | アラーガン | Compositions and methods for disinfecting contact lenses with terpenes |
| JPH08175985A (en) * | 1994-12-26 | 1996-07-09 | Lion Corp | Ophthalmic solution |
| JPH0977656A (en) * | 1995-09-14 | 1997-03-25 | Toshihiro Handa | Aerosol composition for dropping eye lotion |
| JPH09255530A (en) * | 1996-03-25 | 1997-09-30 | Shiseido Co Ltd | Solubilized cosmetic |
| JPH11130667A (en) * | 1997-08-26 | 1999-05-18 | Senju Pharmaceut Co Ltd | Ophthalmic composition for soft contact lens, wetting enhancement of soft contact lens and adsorption suppression of terpenoid |
Cited By (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002049613A3 (en) * | 2000-12-19 | 2003-01-16 | Bausch & Lomb | Method for enhancing integrity of epithelium using retinoic acid |
| JP2003066383A (en) * | 2001-08-30 | 2003-03-05 | Lion Corp | Contact lens wearing liquid |
| JP2005037928A (en) * | 2003-06-26 | 2005-02-10 | Rohto Pharmaceut Co Ltd | Composition of contact lense |
| US8435965B2 (en) | 2005-12-27 | 2013-05-07 | Lion Corporation | Composition for soft contact lens and adsorption suppressing method |
| WO2007077783A1 (en) | 2005-12-27 | 2007-07-12 | Lion Corporation | Composition for soft contact lens and adsorption suppressing method |
| JP2011006348A (en) * | 2009-06-25 | 2011-01-13 | Lion Corp | Therapeutic agent for dry eye |
| US11324757B2 (en) | 2010-03-17 | 2022-05-10 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
| US10555953B2 (en) | 2010-03-17 | 2020-02-11 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
| US11160865B2 (en) | 2010-10-20 | 2021-11-02 | Novaliq Gmbh | Liquid pharmaceutical composition for the delivery of active ingredients |
| US10064944B2 (en) | 2010-11-11 | 2018-09-04 | Novaliq Gmbh | Liquid pharmaceutical composition for the treatment of a posterior eye disease |
| JP2012189993A (en) * | 2011-03-10 | 2012-10-04 | Pegavision Corp | Liquid composition for contact lenses |
| US11844836B2 (en) | 2011-05-25 | 2023-12-19 | Dermaliq Therapeutics, Inc. | Topical pharmaceutical composition based on semifluorinated alkanes |
| US10130707B2 (en) | 2011-05-25 | 2018-11-20 | Novaliq Gmbh | Topical pharmaceutical composition based on semifluorinated alkanes |
| US10813999B2 (en) | 2011-05-25 | 2020-10-27 | Novaliq Gmbh | Topical pharmaceutical composition based on semifluorinated alkanes |
| USRE49758E1 (en) | 2012-01-23 | 2023-12-19 | Novaliq Gmbh | Stabilised protein compositions based on semifluorinated alkanes |
| JP2012145967A (en) * | 2012-05-07 | 2012-08-02 | Lion Corp | Contact lens wetting solution |
| US10576154B2 (en) | 2012-09-12 | 2020-03-03 | Novaliq Gmbh | Semifluorinated alkane compositions |
| JP2015531344A (en) * | 2012-09-12 | 2015-11-02 | ノバリック ゲーエムベーハー | Composition comprising a mixture of semi-fluorinated alkanes |
| US10058615B2 (en) | 2012-09-12 | 2018-08-28 | Novaliq Gmbh | Semifluorinated alkane compositions |
| US12005033B2 (en) | 2012-09-12 | 2024-06-11 | Novaliq Gmbh | Compositions comprising mixtures of semifluorinated alkanes |
| US10449164B2 (en) | 2012-09-12 | 2019-10-22 | Novaliq Gmbh | Methods of treating ocular disorders using semifluorinated alkanes |
| US11583513B2 (en) | 2012-09-12 | 2023-02-21 | Novaliq Gmbh | Semifluorinated alkane compositions |
| US10369117B2 (en) | 2012-09-12 | 2019-08-06 | Novaliq Gmbh | Compositions comprising mixtures of semifluorinated alkanes |
| US11987623B2 (en) | 2013-07-23 | 2024-05-21 | Novaliq Gmbh | Stabilized antibody compositions |
| US10273298B2 (en) | 2013-07-23 | 2019-04-30 | Novaliq Gmbh | Stabilized antibody compositions |
| US11154513B2 (en) | 2015-09-30 | 2021-10-26 | Novaliq Gmbh | Semifluorinated compounds |
| US10682315B2 (en) | 2015-09-30 | 2020-06-16 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
| US11357738B2 (en) | 2015-09-30 | 2022-06-14 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
| US10525159B2 (en) | 2016-05-26 | 2020-01-07 | Ophtecs Corporation | Liquid preparation for contact lenses comprising hydrolyzed hyaluronic acid derivative and cationic bactericide |
| US10507132B2 (en) | 2016-06-23 | 2019-12-17 | Novaliq Gmbh | Topical administration method |
| US11684589B2 (en) | 2016-09-22 | 2023-06-27 | Novaliq Gmbh | Pharmaceutical compositions for use in the therapy of blepharitis |
| US11400132B2 (en) | 2016-09-23 | 2022-08-02 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| US10813976B2 (en) | 2016-09-23 | 2020-10-27 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| US11723861B2 (en) | 2017-09-27 | 2023-08-15 | Novaliq Gmbh | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases |
| JP7310113B2 (en) | 2017-10-04 | 2023-07-19 | ライオン株式会社 | Ophthalmic composition, method for producing the same, and method for suppressing adsorption |
| JP2019065008A (en) * | 2017-10-04 | 2019-04-25 | ライオン株式会社 | Ophthalmic composition, method for producing the same, and method for suppressing adsorption |
| US11896559B2 (en) | 2017-10-04 | 2024-02-13 | Novaliq Gmbh | Opthalmic compositions comprising F6H8 |
| US11576893B2 (en) | 2018-03-02 | 2023-02-14 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
| WO2019216381A1 (en) * | 2018-05-09 | 2019-11-14 | ロート製薬株式会社 | Ophthalmic composition |
| US11413323B2 (en) | 2018-10-12 | 2022-08-16 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001158734A (en) | Composition for ophthalmology and method for inhibiting adsorption to soft contact lens | |
| JP5549669B2 (en) | Ophthalmic composition, dry eye treatment and method for stabilizing vitamin A | |
| JP4748289B2 (en) | Eye drops, ophthalmic composition, and adsorption suppression method | |
| JP2001187728A (en) | Ophthalmic composition | |
| JP3142842B1 (en) | Ophthalmic composition and method for suppressing adsorption to soft contact lens | |
| JP5842593B2 (en) | Ophthalmic composition | |
| JP2009173638A (en) | Method of stabilizing ophthalmic composition and vitamin a family | |
| JP5729109B2 (en) | Ophthalmic composition for soft contact lenses | |
| JP3846537B2 (en) | Contact lens mounting solution | |
| JP2011213599A (en) | Ophthalmic composition for soft contact lens | |
| JP3175742B1 (en) | Ophthalmic composition for contact lenses | |
| JP2001187733A5 (en) | ||
| JP2002316926A (en) | Ophthalmic composition for contact lens and method for mitigating ocular irritation | |
| JP2001322936A (en) | Ophthalmic composition | |
| JP2001261578A (en) | Ophthalmic composition | |
| JP2011246383A (en) | Ophthalmologic formulation for alleviation of tired eyes of contact lens wearer | |
| JP2001158750A (en) | Method for improving sustainability of ophthalmic composition and anti-allergic medicine | |
| JP4844706B2 (en) | Ophthalmic composition | |
| JP4849288B2 (en) | Eye drops and tear film stabilizer | |
| JP2001253822A (en) | Corneal cell restorer composition | |
| JP5041761B2 (en) | Ocular mucosa application | |
| JP2002114711A (en) | External preparation composition | |
| JP5092138B2 (en) | Contact lens mounting fluid | |
| JP2005008596A (en) | Ophthalmological composition | |
| JP2001131055A (en) | Liquid agent, removal of white cloudiness of liquid agent and acceleration of trans-mucous membrane absorption of liquid agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060808 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100127 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100329 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100329 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100609 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101110 |